Objectives: To establish the prevalence of the AmpC b-lactamase phenotype in clinical isolates of Escherichia coli and characterize the genetic resistance mechanisms causing the observed phenotype.
Introduction
AmpC b-lactamases belong to Ambler class C and are causing concern because they mediate resistance to a broad spectrum of antibiotics comparable to the extended-spectrum b-lactamases (ESBLs). In Escherichia coli the chromosomal ampC gene is normally expressed in low amounts not causing clinical resistance, because the promoter is weak and the gene contains a transcriptional attenuator. However, mutations in the promoter have been reported to play an important role in E. coli resistance to b-lactams by increasing ampC transcription. 1 Such genes conferring AmpC hyperproduction are here designated cAmpC. Additionally, extended-spectrum AmpC (ESAC) b-lactamases with increased hydrolytic activity against ceftazidime and cefepime have been described in E. coli. The broadened substrate activity of these enzymes is due to structural modifications in the active site. 2 Finally, the presence of a plasmid-mediated ampC gene (pAmpC) is increasingly frequently identified in E. coli. 3 Originally such genes are thought to have been mobilized to plasmids from the chromosomal ampC genes of organisms such as Citrobacter freundii, Enterobacter cloacae, Hafnia alvei, Morganella morganii and Aeromonas spp. 3 The aim of the present study was to examine the prevalence of E. coli isolates with an AmpC phenotype among clinical isolates in our department. Additionally, we analysed the causes for the observed AmpC phenotype molecularly, determined the relative contribution of pAmpC and cAmpC and compared the susceptibility patterns associated with the different genotypes. Hospital, Denmark. All isolates displaying reduced susceptibility to cefpodoxime, cefuroxime, ceftriaxone or ceftazidime were screened for AmpC hyperproduction by cefoxitin susceptibility testing. Isolates with a cefoxitin inhibition zone ,20 mm were designated as possible AmpC hyperproducers and were further tested by the AmpC disc test method as described previously. 4 Isolates with a positive AmpC disc test were selected for further analysis. MICs were determined using Etest (AB Biodisk) according to the manufacturer's instructions.
Materials and methods

Between
For isoelectric focusing (IEF) analysis bacterial suspensions were disrupted by vortexing with Garnet Bead Tubes 0.15 mm Sample (Mo Bio Laboratories, USA) and cleared by centrifugation. IEF was done using standard methods. 5 PCR amplification for bla SHV , bla TEM and bla CTX-M was performed as previously described. 5, 6 PCR-positive samples for bla TEM were sequenced using the same primers as for PCR. Positive samples in the multiplex PCR for bla CTX-M were re-amplified using primers specific for either group 1 or group 9 where appropriate [ Table S1 , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)], encompassing the entire reading frame and sequenced using the same primers as for amplification. Multiplex amplification of the six families of plasmid-mediated ampC was performed as described previously.
7 PCR-positive strains were re-amplified by use of specific primers for amplification of the entire bla AmpC gene as previously described. 7 Sequencing of the resulting PCR products was done using the same primers as for PCR together with a set of internal primers designed in this study (Table S1 ). Chromosomal ampC promoter mutations were examined by PCR and sequencing, as previously described. 8 Briefly, a set of primers were used to amplify and sequence a 271 bp fragment (position 2150 to þ120) from the E. coli ampC promoter containing the 235 box, the 210 box and the attenuator. 1 PCR amplifications of ampC genes were performed with primers described by Mammeri et al.,
2 yielding a 1315 bp amplification product that contained the entire ampC gene of E. coli.
Strains positive for bla CMY-2 were analysed by multilocus sequence typing (MLST) following the procedure described by Wirth et al.
9
Primers specified at the E. coli MLST web site (http://mlst.ucc.ie/mlst/ dbs/Ecoli/documents/primersColi_html) were used for gene amplification and sequencing except for mdh and icd for which primers described by Nicolas-Chanoine et al. 10 were used.
Results and discussion
In the study period, specimens obtained from 6356 individual patients yielded positive cultures for E. coli. Seventy-four isolates displaying decreased susceptibility to third-generation cephalosporins and cefoxitin were further tested using the AmpC disc test. In all, 24/6356 (0.4%) isolates displayed a positive AmpC disc test and were selected for further analysis. IEF was done to confirm the expression of AmpC-type b-lactamase in the selected strains. AmpC-type b-lactamases display a pI of 9. All isolates with an AmpC phenotype except E23 expressed a b-lactamase with a pI of 8.9 (Table 1) . No b-lactamases were detected in the fully susceptible control strain E. coli ATCC 25922. Thus, hyperproduction of AmpC was confirmed in 23/24 strains. Several isolates had more than one b-lactamase that could be visualized by IEF. Eleven strains displayed bands with pI 5.4, and sequencing identified these as bla TEM-1 . Five strains displayed bands with an apparent pI of 7.6 -7.9. Sequencing identified these as two bla CTX-M-14 genes, two bla CTX-M-15 genes and one bla CTX-M-55 gene. E04 and E23 displayed an unidentified b-lactamase with a pI of 6.5 whereas E01, E16, E22, E24 and E33 displayed an unidentified b-lactamase with a pI of 7.4. All strains were negative for bla SHV by PCR.
All 24 isolates were screened for pAmpC by multiplex PCR as described previously. 7 Four isolates (16.7%) were positive for bla CIT . DNA sequencing of the entire gene showed 100% identity with the bla CMY-2 gene in all four isolates. All four bla CMY-2 -positive isolates also contained bla TEM-1 . To investigate if these isolates were clonally related MLST was performed on bla CMY-2 -positive strains. All four strains belonged to individual sequence types (STs). E16 belonged to ST46 (clonal complex, ST46 with an insertion sequence IS1 in the fumC gene), E22 belonged to ST48 (clonal complex, ST10), E29 belonged to ST652 (clonal complex, none) and E33 belonged to ST448 (clonal complex, ST448). This indicates that bla CMY-2 -positive strains occurred sporadically in the study period.
To investigate the extent to which hyperproduction of cAmpC contributed to the observed phenotype (Table 1) we sequenced the promoter region of the chromosomal ampC gene to identify sequence elements associated with increased strength of the promoter ( Table 2) . 1 All of the ampC multiplex PCR-negative isolates with an AmpC phenotype and confirmed AmpC expression by IEF had mutations or insertions in their control regions. Group 1 comprising five isolates had a 1 bp insertion at either position 221 or 213, shifting the length of the spacer region to the optimal 17 bp between the 235 and 210 boxes. These displayed moderately decreased susceptibility to cephalosporins [geometric mean MICs: cefuroxime, 16 mg/L; cefotaxime, 2.6 mg/L; and ceftazidime, 1.3 mg/L (Table 1) ]. Group 2 comprising three isolates had mutations in the ampC promoter region at position 232, changing the 235 box. Additionally, one of these isolates had mutations in the attenuator region (þ17 to þ37). This group also displayed a moderately decreased susceptibility to cephalosporins [geometric mean MICs: cefuroxime, 32 mg/L; cefotaxime, 5.0 mg/L; and ceftazidime, 2.5 mg/L ( AmpC-type b-lactamases with broadened substrate activity due to mutations in the structural gene are called ESACs and exhibit extended hydrolysis of b-lactams.
2 Sequencing of the ampC coding region revealed that 10 isolates had mutations in the ampC coding region; however, all remained susceptible to cefepime except for 3 isolates, which contained an additional bla CTX-M to explain resistance (Table 1) .
Phylogenetic reconstruction based upon the sequence information from the ampC promoter and coding region showed that most isolates yielded unique sequences (results not shown). E04 and E20 yielded identical sequences, as did E06, E12 and E13. In the case of E04 and E20 these were isolated 3 months apart in different wards and contained different bla CTX-M . In the case of E06, E12 and E13 an epidemiological link between E12 and E13 could be suspected, as these were isolated from the same AmpC-hyperproducing E. coli ward 1 day apart. However, the majority of isolates occurred sporadically during the study period.
In conclusion, E. coli strains that hyperproduce AmpC either caused by the acquisition of bla CMY-2 or as a result of promoter mutations associated with hyperproduction of chromosomally encoded bla AmpC occur sporadically in Denmark. In the present study 5/24 isolates with an AmpC phenotype had a 1 bp insertion between the 210 and 235 boxes (group 1 cAmpC) and 3/24 isolates had mutations in the 235 box to a consensus box (group 2 cAmpC). These mutation patterns in the present study were only associated with low-level resistance. In other studies isolates with 242 promoter mutations have predominated. 2, 5 It is likely that different selection criteria for study strains contributed to the observed differences in prevalence. As hyperproduction of AmpC is associated with clinically significant resistance, their detection, proper reporting and monitoring of future epidemiology are important.
